99419-31-5

Basic information

• Product Name: 3-OXETANECARBOXALDEHYDE, 3-METHYL-
• Synonyms: 3-OXETANECARBOXALDEHYDE, 3-METHYL-;3-methyloxetane-3-carbaldehyde;3-Methyl-3-oxetanecarboxa...;3-Methyl-3-oxetanecarboxaldehyde;3-Methyl-3-oxetane-carbaldehyde
• CAS NO: 99419-31-5
• Molecular Formula: C₅H₈O₂
• Molecular Weight: 100.12
• Mol File: 99419-31-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 63 °C(Press: 30 Torr)
• Appearance: /
• Density: 1.150±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 3-OXETANECARBOXALDEHYDE, 3-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-OXETANECARBOXALDEHYDE, 3-METHYL-(99419-31-5)
• EPA Substance Registry System: 3-OXETANECARBOXALDEHYDE, 3-METHYL-(99419-31-5)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-51/53
• Safety Statements: 61
• RIDADR: UN3077
• Hazardous Substances Data: 99419-31-5(Hazardous Substances Data)

Usage

General Description

3-Oxetanecarboxaldehyde, 3-methyl- is a chemical compound with the molecular formula C5H8O2. It is a clear, colorless liquid with a characteristic odor and is used in the production of various pharmaceuticals and organic compounds. This chemical is mainly used as a reagent in organic synthesis and in the pharmaceutical industry to create complex molecular structures. It is also known to be an intermediate in the synthesis of odorants and flavor compounds. 3-Oxetanecarboxaldehyde, 3-methyl- is an important chemical for various industrial applications and is handled with care due to its reactivity and potential hazards.

Upstream product

• 3143-02-0 3-hydroxymethyl-3-methyloxethane 

Downstream Products

• 1290541-27-3 3-ethynyl-3-methyloxetane 
• 1215868-94-2 (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine 

Relevant articles and documents

Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach

ATAD2 is an ATPase that is overexpressed in a variety of cancers and associated with a poor patient prognosis. This protein has been suggested to function as a cofactor for a range of transcription factors, including the proto-oncogene MYC and the androgen receptor. ATAD2 comprises an ATPase domain, implicated in chromatin remodelling, and a bromodomain which allows it to interact with acetylated histone tails. Dissection of the functional roles of these two domains would benefit from the availability of selective, cell-permeable pharmacological probes. An in silico evaluation of the 3D structures of various bromodomains suggested that developing small molecule ligands for the bromodomain of ATAD2 is likely to be challenging, although recent reports have shown that ATAD2 bromodomain ligands can be identified. We report a structure-guided fragment-based approach to identify lead compounds for ATAD2 bromodomain inhibitor development. Our findings indicate that the ATAD2 bromodomain can accommodate fragment hits (Mr 200) that yield productive structure-activity relationships, and structure-guided design enabled the introduction of selectivity over BRD4.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.